Status and phase
Conditions
Treatments
About
The purpose of this study is to see if it is safe and effective to give Viracept plus stavudine (d4T) plus lamivudine (3TC) to HIV-positive women with a CD4 count <= 400 cells/mm3. This study also examines how the body handles Viracept when given with d4T and 3TC.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria
Patients must have:
Exclusion Criteria
Prior Medication:
Excluded:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal